Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized multinational double-blind placebo-controlled parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis

Next Previous
X
Search
Trial Profile

A randomized multinational double-blind placebo-controlled parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriflunomide (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Apr 2010 Results published at 62nd Annual Meeting of the American Academy of Neurology.
    • 29 Dec 2009 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 29 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top